Should You Stay Invested in J&J Stock After Q4 Beat & Solid Guidance?
unknown
📅 Published: 2026-01-28 16:10
📰 Source: Yahoo
📝 Words: 24
📝 Article Content
JNJ beat Q4 expectations and guided 2026 sales to be in the range of $100-$101B, with Innovative Medicine and MedTech growth offsetting Stelara LOE.
📄 Summary
JNJ beat Q4 expectations and guided 2026 sales to be in the range of $100-$101B, with Innovative Medicine and MedTech growth offsetting Stelara LOE.
Scraping Metadata:
Scraped At:
Unknown
Created At:
2026-01-29 16:37:47
Updated At:
2026-01-29 16:37:47
Scraping Job ID:
N/A
Stock Mentions:
JNJ - Johnson & Johnson
Relevance: N/A